Biotechnology company Genentech, part of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), revealed on Thursday that its Phase II/III SKYSCRAPER-06 trial testing a combination therapy for lung cancer did not meet its primary goals.

The treatment, tiragolumab plus Tecentriq and chemotherapy, showed reduced effectiveness compared to the standard treatment.

While the safety profile remained acceptable, Genentech will halt the trial due to these disappointing efficacy results. The company will inform patients and investigators, share findings with health authorities and present them at a medical conference.